ABSTRACT
Vascular injury is a menacing element of acute respiratory distress syndrome (ARDS) pathogenesis. To better understand the role of vascular injury in COVID-19 ARDS, we used lung autopsy immunohistochemistry and blood proteomics from COVID-19 subjects at distinct timepoints in disease pathogenesis, including a hospitalized cohort at risk of ARDS development (“at risk”, N=59), an intensive care unit cohort with ARDS (“ARDS”, N=31), and a cohort recovering from ARDS (“recovery”, N=12). COVID-19 ARDS lung autopsy tissue revealed an association between vascular injury and platelet-rich microthrombi. This link guided the derivation of a protein signature in the at risk cohort characterized by lower expression of vascular proteins in subjects who died, an early signal of vascular limitation termed the maladaptive vascular response. These findings were replicated in COVID-19 ARDS subjects, as well as when bacterial and influenza ARDS patients (N=29) were considered, hinting at a common final pathway of vascular injury that is more disease (ARDS) then cause (COVID-19) specific, and may be related to vascular cell death. Among recovery subjects, our vascular signature identified patients with good functional recovery one year later. This vascular injury signature could be used to identify ARDS patients most likely to benefit from vascular targeted therapies.
Competing Interest Statement
AMKC is a cofounder, stock holder and serves on the Scientific Advisory Board for Proterris, which develops therapeutic uses for carbon monoxide. AMKC also has a use patent on CO. The spouse of MEC is a cofounder and shareholder, and serves on the Scientific Advisory Board of Proterris, Inc. All other authors declare no competing interests.
Funding Statement
This work is supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation. JK is supported by the National Institute of Aging of the National Institutes of Health under award 1U19AG063744.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review board (IRB) at WCM (20-05022072, 20-03021681, and 1811019771). Written informed consent was received from all participants prior to inclusion in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Shared first authorship
Conflict of Interest Statement AMKC is a cofounder, stock holder and serves on the Scientific Advisory Board for Proterris, which develops therapeutic uses for carbon monoxide. AMKC also has a use patent on CO. The spouse of MEC is a cofounder and shareholder, and serves on the Scientific Advisory Board of Proterris, Inc. All other authors declare no competing interests.
Data Availability
The datasets used for this study include sensitive patient information extracted from the electronic health record. They are therefore subject to federal legislation that limits our ability to make them publicly available, even after being subjected to deidentification techniques. To request access to the de-identified minimal datasets underlying the findings illustrated in our paper, interested and qualified researchers should contact Information Technologies & Services Department of Weill Cornell Medicine support{at}med.cornell.edu. The R Code used to generate all the statistical results presented in this paper is available at https://github.com/krumsieklab/covid-vascular-injury.